T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma

The purpose of this study is to assess wether it is safe and feasible to treat patients with tumor infiltrating lymphocytes that have been silenced for PD-1, using CRISPR-Cas9.

Trial Details

NCT ID
NCT06783270
Phase
PHASE1
Sponsor
Inge Marie Svane
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • TIL therapy
Locations (sample)
  • Herlev, Capital Region, Denmark|55.72366,12.43998

Key Eligibility Criteria

  • Histologically confirmed inoperable or metastatic melanoma (stage IIIc or IV).
  • Progressive disease after standard treatment with anti-PD-1 check-point inhibition or combination of aforementioned with anti-CTLA-4 check-point in…
  • Age: 18 - 75 years at the time of signed Informed consent.
  • ECOG performance status of ≤1 (Appendix 2).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →